NCT03010358 2023-08-08Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaOHSU Knight Cancer InstitutePhase 1/2 Completed24 enrolled 16 charts
NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts
NCT01326702 2019-12-16Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsNational Cancer Institute (NCI)Phase 1/2 Completed43 enrolled 18 charts
NCT00089076 2014-05-30MDX-010 in Treating Patients With Recurrent or Refractory LymphomaNational Cancer Institute (NCI)Phase 1/2 Terminated18 enrolled 11 charts